 Dermata Therapeutics Inc DRMA has requested the FDA to waive the requirements to complete a 90-day dermal minipig study and a standard dermal pharmacokinetics study before the End of Phase 2 meeting for its DMT310 acne program. Get the Inside Access Traders Are Using to Profit More and Win Bigger. 